Schulman IRB Selected as National IRB for Cancer MoonShot
Schulman IRB will serve as the IRB of record for all participating research sites.
Schulman IRB has been selected as the national IRB for the Cancer MoonShot 2020 program.
The Cancer Moonshot 2020 coalition was formed to accelerate next generation immunotherapy and will design, initiate and complete randomized clinical trials at all stages of cancer in up to 20 tumor types in as many as 20,000 patients in multiple Phase I-III trials by the year 2020. Schulman IRB will serve as the IRB of record for all participating research sites. Schulman's IRB membership includes multiple oncologists and research professionals experienced in oncology research. These experts are led by an IRB Chair with extensive oncology experience in an institutional setting.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
